Loading…
Addex Therapeutics Ltd is projected to rise to $6.39 by 2027, a +1% move from its current price of $6.34. ADXN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.14 | $6.34 | $6.55 | +0.06% |
| Jul 14 | $6.06 | $6.35 | $6.64 | +0.12% |
| Jul 15 | $6.01 | $6.35 | $6.72 | +0.18% |
| Jul 16 | $5.96 | $6.35 | $6.78 | +0.23% |
| Jul 17 | $5.92 | $6.36 | $6.84 | +0.29% |
| Jul 18 | $5.88 | $6.36 | $6.89 | +0.35% |
| Jul 19 | $5.84 | $6.37 | $6.93 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.84 | $6.37 | $6.93 | +0.41% |
| Week 2 | $5.66 | $6.39 | $7.21 | +0.82% |
| Week 3 | $5.53 | $6.42 | $7.44 | +1.23% |
| Week 4 | $5.43 | $6.44 | $7.65 | +1.65% |
| Week 5 | $5.34 | $6.47 | $7.83 | +2.06% |
| Week 6 | $5.27 | $6.50 | $8.01 | +2.48% |
| Week 7 | $5.20 | $6.52 | $8.18 | +2.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Addex Therapeutics Ltd is a biotechnology company that discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.
Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia; and ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreements with Janssen Pharmaceuticals Inc. for the development of mGlu2 PAM compounds for the treatment of human health, and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases.
Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
ADXN trades as Addex Therapeutics Ltd in the Healthcare sector as a small-cap biotechnology stock. It currently prices at $6.00 per share and carries a market cap of $7.6M, ranking 5188 by market capitalization.
The asset sits in the healthcare space with a focus on neurological conditions, supported by a pipeline that includes Dipraglurant, ADX71149, and a GABAB PAM program with licensing relationships to Janssen and Indivior.
Forecasts project a path of rising averages and potential upside over the coming years, with a near-term neutral stance in 2026 and deeper bullish momentum emerging in later years. The longer-horizon view envisions substantial upside, with multi-year average prices climbing from the mid-single digits toward double-digit and higher levels by 2050.
A major floor 18.5% below — a decisive break under it would weaken the trend.
The nearest floor, 10.1% below — buyers have tended to step in here.
The nearest ceiling, 7.6% above — a clean break opens room to run.
A major ceiling 16.8% above — clearing it would confirm fresh momentum.
Key ADXN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADXN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.94 | Buy | $6.02 | Buy |
| MA 10 | $5.90 | Buy | $5.98 | Buy |
| MA 20 | $6.06 | Buy | $6.07 | Buy |
| MA 50 | $6.46 | Sell | $6.33 | Buy |
| MA 100 | $6.61 | Sell | $6.68 | Sell |
| MA 200 | $7.51 | Sell | $7.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.87 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 88.35 | Neutral |
| Williams %R (14) | -21.95 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -1.71 | Sell |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 78.05 | Neutral |
| TRIX (15) | -0.41 | Sell |
| Awesome (5,34) | -0.31 | Sell |
| Ultimate (7,14,28) | 79.13 | Sell |
| Momentum (10) | 0.40 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 6.03 | Buy |
| ADX (14) | 13.08 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 40 indicating modest near-term momentum.
The stock trades around a middle of its recent trading range, with a SMA50 of $6.65 and a SMA200 of $7.69, suggesting near-term resistance above the current price. Support is noted at $5.86, with a resistance level at $7.00.
Over the last 30 days, the price has traded within a range of $4.69 to $7.68, highlighting a contained short-term volatility pattern. The stock carries an annualized volatility of 70%, underscoring high price variability relative to broader markets.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.66 | $6.34 | $8.46 | 0% | Neutral | |
| $5.00 | $6.39 | $8.69 | +1% | Neutral | |
| $5.22 | $6.90 | $9.79 | +9% | Neutral | |
| $6.15 | $8.35 | $12.26 | +32% | Bullish | |
| $6.61 | $9.22 | $13.90 | +45% | Bullish | |
| $7.51 | $10.71 | $16.54 | +69% | Bullish | |
| $7.83 | $11.40 | $18.01 | +80% | Bullish | |
| $7.19 | $10.68 | $17.19 | +68% | Bullish | |
| $7.28 | $11.02 | $18.07 | +74% | Bullish | |
| $7.53 | $11.61 | $19.36 | +83% | Bullish | |
| $10.53 | $17.67 | $31.57 | +179% | Bullish | |
| $18.06 | $35.17 | $69.46 | +455% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.66 | $6.34 | $7.62 | +0.00% |
| August 2026 | $5.59 | $6.63 | $8.10 | +4.54% |
| September 2026 | $5.59 | $6.69 | $8.27 | +0.88% |
| October 2026 | $5.34 | $6.43 | $8.05 | -3.82% |
| November 2026 | $5.31 | $6.43 | $8.12 | -0.02% |
| December 2026 | $5.45 | $6.65 | $8.46 | +3.36% |
Click any year to see its month-by-month ADXN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ADXN price prediction for 2026 points to an average of $6.34 (low $5.66, high $8.46) — a potential gain of 0% on today's $6.34. Price action looks broadly range-bound.
In 2027, ADXN is projected to trade between $5.00 and $8.69, averaging $6.39 — a potential gain of +1% from today's $6.34. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
Addex Therapeutics Ltd's 2028 outlook centres on $6.90, within a $5.22 to $9.79 range. That is up +8% on the projected 2027 average. That marks a +9% change versus current levels. Price action looks broadly range-bound.
By 2029, ADXN could reach as high as $12.26, with a base case around $8.35 and support toward $6.15 — roughly +32% from $6.34. Buyers look set to stay in control over this stretch.
Expect ADXN to range from $6.61 to $13.90 through 2030. The $9.22 average target implies a +45% move from current prices. That is up +10% on the projected 2029 average. Momentum favours further upside here.
The ADXN price prediction for 2031 points to an average of $10.71 (low $7.51, high $16.54) — a potential gain of +69% on today's $6.34. Buyers look set to stay in control over this stretch.
In 2032, ADXN is projected to trade between $7.83 and $18.01, averaging $11.40 — a potential gain of +80% from today's $6.34. That is up +7% on the projected 2031 average. Momentum favours further upside here.
Addex Therapeutics Ltd's 2033 outlook centres on $10.68, within a $7.19 to $17.19 range. That is -6% versus the projected 2032 average. That marks a +68% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ADXN could reach as high as $18.07, with a base case around $11.02 and support toward $7.28 — roughly +74% from $6.34. Momentum favours further upside here.
Expect ADXN to range from $7.53 to $19.36 through 2035. The $11.61 average target implies a +83% move from current prices. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ADXN price prediction for 2040 points to an average of $17.67 (low $10.53, high $31.57) — a potential gain of +179% on today's $6.34. Momentum favours further upside here.
In 2050, ADXN is projected to trade between $18.06 and $69.46, averaging $35.17 — a potential gain of +455% from today's $6.34. That is up +99% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADXN today (≈ 157.728707 ADXN) could be worth
$5,547.43
+$4,547.43 (+455%) by 2050 · US Dollar
Based on the average projected ADXN price of $35.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADXNwould be worth at today's price.
$1,000 invested in ADXN on Jul 10, 2025 (≈ 111.856829 ADXN) would be worth
$709.17
-$290.83 (-29.1%) today · 0.71× · US Dollar
Based on a ADXN entry price of $8.94 vs. today's $6.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.79 | $1,094.99 | +9.5% |
| 1 month ago | $6.5 | $975.38 | -2.5% |
| 3 months ago | $6.6 | $960.61 | -3.9% |
| 6 months ago | $8.23 | $770.35 | -23.0% |
| 1 year ago | $8.94 | $709.17 | -29.1% |
| All time (5.0y) ago | $190 | $33.37 | -96.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADXN forecast.
Our base-case forecast reaches $13.00 around 2040.
Implied market cap at $13.00: $16.46M
The multi-year forecast shows a bullish trajectory beginning in the late 2020s and extending through 2050. The 2026 forecast yields an average of $6.00 with a 0.0% ROI and NEUTRAL sentiment, followed by 2027 at $5.77 with -3.9% ROI and NEUTRAL sentiment. The outlook improves from 2028 onward, with 2028 at $6.27 (4.5% ROI) and 2029 at $7.41 (23.5% ROI) with a bullish tilt.
By 2030, the average price is projected to $8.08 with a 34.7% ROI and bullish sentiment, rising further to 2031 at $9.85 (64.2% ROI) and 2032 at $10.16 (69.3% ROI). The 2033 average is $8.96 (49.3% ROI) and 2034 is $9.69 (61.5% ROI), with 2035 at $9.90 (65.0% ROI) and continued bullish momentum.
Longer-horizon figures show substantial upside, with 2040 averaging $15.34 (155.7% ROI) and 2050 averaging $28.85 (380.8% ROI). Max values in these years extend well above the averages, e.g., 2030 max $12.65, 2032 max $16.73, 2040 max $28.95, and 2050 max $60.73. These are estimates, not guarantees, and reflect potential upside alongside the asset’s inherent risks and volatility.
Tap a question to reveal the answer.
The forecast shows an average price of $8.08 with a max of $12.65 and a min of $5.60, and a bullish sentiment. The ROI is 34.7%.
The forecast includes a neutral outlook in 2026 (avg $6.00, ROI 0%) with a shift to bullish sentiment from 2029 onward (avg rising to $8.08 by 2030, $28.85 by 2050). These are estimates, not guarantees.
Yes. The forecast shows max values above $10 in several years, including 2030 max $12.65 and 2032 max $16.73, with 2040 max $28.95 and 2050 max $60.73.
Current price is $6.00 and market cap is $7.6M.
RSI14 is 40 with NEUTRAL sentiment. SMA50 is $6.65 and SMA200 is $7.69, with support at $5.86 and resistance at $7.00. The 30-day range is $4.69 to $7.68, and annualized volatility is 70%.
Addex Therapeutics Ltd Community Discussion
0Share your Addex Therapeutics Ltd price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.